5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The Ophthalmology Drug and Device Market is segmented by Product (Devices and Drugs), Disease, and Geography.
Fastest Growing Market:
The ophthalmology drug and device market is expected to witness a CAGR of 5.5% during the forecast period. Certain factors that are driving the growth of the market include demographic shift, the impact of the prevalence of eye disease, technological advancements in the field of ophthalmology, and rising geriatric population. The aging population is expected to burden all areas of healthcare, and ophthalmologists provide approximately 90% of their procedure-based services to seniors.
This report forecasts revenue growth at global, regional, and country-level, and it provides an analysis of the latest industry trends in each of the sub-segments. This study is segmented on the basis of disease, product type, and geography.
|Age-Related Macular Degeneration|
Report scope can be customized per your requirements. Click here.
Based on disease, the market is segmented into glaucoma, cataract, age-related macular degeneration, inflammatory diseases, refractive disorders and other diseases. According to the Royal College of Ophthalmologists, around 330,000 cataract operations are performed each year in England alone. The same source stated that around 30% of people aged 65 years or more have a visually impairing cataract in one or both eyes. Some people tend to have a much higher prevalence of cataracts. For instance, 77% of the British people, aged 42 years or older, originating from the Indian subcontinent have cataracts. There is a threefold variation in the number of people having cataract surgery across England, owing to differences in health commissioning policies.
Similarly, as per the American Academy of Ophthalmology, it is estimated that by 2050, around 50 million people in the United States are expected to suffer from cataract, which is one of the leading cause of blindness in the United States. Cataract surgery remains the most effective way to help restore vision for the people with cataracts. Hence, with the rising burden of eye disease, the market is expected to grow in the forecast period.
To understand key trends, Download Sample Report
Due to the presence of well-established healthcare facilities, the rise in geriatric population in the region, and certain other factors, North America is dominating the ophthalmology drug and device market. Owing to the constant increase in the American elderly population, as well as a movement toward vision correction and its usage among key demographics, an absolute increase in rates for most types of eyewear was observed in the United States.
Additionally, the Government of Canada stated that the average revenue of the small and medium-sized enterprises, primarily engaged in retailing and fitting prescription eyeglasses, was found to be USD 565.2 thousand, in 2016, whereas the profit was around 77%-78%.
The presence of key players in this region is a key propeller for the market growth. For instance, according to an article published in BrightFocus Foundation, in 2017, more than 3 million Americans were suffering from glaucoma. Hence, these factors are expected to drive the market growth in the forecast period.
To understand geography trends, Download Sample Report.
The ophthalmology drug and device market, which is significantly competitive, consists of a number of major players. Companies, such as Alcon Inc., Bausch Health Companies Inc., Carl Zeiss Meditec AG, Essilor International SA, Haag-Streit Group, Johnson & Johnson, Nidek Co. Ltd, Topcon Corporation, and Ziemer Group AG, are having a well-established presence in the global market.
Several developments have been taking place in the market. For instance, in November 2017, Bausch & Lomb got Vyzulta approved for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Moreover, in November 2017, Zeiss introduced the cloud-based cataract surgery planning platform, Veracity Surgical, and announced the integration with leading EMRs.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Demographic Shift and Impact of Prevalence of Eye Disease
4.2.2 Technological Advancements in the Field of Ophthalmology
4.2.3 Rising Geriatric Population
4.3 Market Restraints
4.3.1 Increasing Healthcare Costs
4.3.2 Strict FDA Guidelines for Drug Approval
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
220.127.116.11 Surgical Devices
18.104.22.168.1 Intraocular Lenses
22.214.171.124.2 Ophthalmic Lasers
126.96.36.199.3 Other Surgical Devices
188.8.131.52 Diagnostic Devices
184.108.40.206 Glaucoma Drugs
220.127.116.11 Retinal Disorder Drugs
18.104.22.168 Dry Eye Drugs
22.214.171.124 Allergic Conjunctivitis and Inflammation Drugs
126.96.36.199 Other Drugs
5.2 By Disease
5.2.3 Age-Related Macular Degeneration
5.2.4 Inflammatory Diseases
5.2.5 Refractive Disorders
5.2.6 Other Diseases
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East & Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Alcon Inc.
6.1.2 Bausch Health Companies Inc.
6.1.3 Carl Zeiss Meditec AG
6.1.4 Essilor International SA
6.1.5 Haag-Streit Group
6.1.6 Johnson & Johnson
6.1.7 Nidek Co. Ltd
6.1.8 Topcon Corporation
6.1.9 Ziemer Group AG
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments